JP7176960B2 - サルブタモール含有眼科用医薬 - Google Patents

サルブタモール含有眼科用医薬 Download PDF

Info

Publication number
JP7176960B2
JP7176960B2 JP2018568424A JP2018568424A JP7176960B2 JP 7176960 B2 JP7176960 B2 JP 7176960B2 JP 2018568424 A JP2018568424 A JP 2018568424A JP 2018568424 A JP2018568424 A JP 2018568424A JP 7176960 B2 JP7176960 B2 JP 7176960B2
Authority
JP
Japan
Prior art keywords
composition
administered
salbutamol
eye
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018568424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524679A (ja
JP2019524679A5 (enExample
Inventor
ラオフ・レキク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019524679A publication Critical patent/JP2019524679A/ja
Publication of JP2019524679A5 publication Critical patent/JP2019524679A5/ja
Application granted granted Critical
Publication of JP7176960B2 publication Critical patent/JP7176960B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018568424A 2016-06-27 2017-06-27 サルブタモール含有眼科用医薬 Expired - Fee Related JP7176960B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TNTN2016/0259 2016-06-27
TN2016000259A TN2016000259A1 (en) 2016-06-27 2016-06-27 Salbutamol (albuterol) eye protective medicament.
PCT/IB2017/000779 WO2018007864A1 (en) 2016-06-27 2017-06-27 Salbutamol-containing ophthalmic medicament

Publications (3)

Publication Number Publication Date
JP2019524679A JP2019524679A (ja) 2019-09-05
JP2019524679A5 JP2019524679A5 (enExample) 2020-02-27
JP7176960B2 true JP7176960B2 (ja) 2022-11-22

Family

ID=59416735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568424A Expired - Fee Related JP7176960B2 (ja) 2016-06-27 2017-06-27 サルブタモール含有眼科用医薬

Country Status (7)

Country Link
US (1) US11484513B2 (enExample)
EP (1) EP3474836B1 (enExample)
JP (1) JP7176960B2 (enExample)
CN (1) CN110114066B (enExample)
MA (1) MA45457A (enExample)
TN (1) TN2016000259A1 (enExample)
WO (1) WO2018007864A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119097618A (zh) * 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
KR20220018484A (ko) * 2019-06-10 2022-02-15 제니비젼 인크. 시력 장애를 치료하기 위한 방법 및 제형
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
JP7066293B2 (ja) * 2019-11-12 2022-05-13 株式会社ファンケル サーチュイン１（ｓｉｒｔ１）発現増強用組成物
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
KR20230015433A (ko) * 2020-05-22 2023-01-31 인트라바이오 리미티드 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물
EP4694929A1 (en) * 2023-04-08 2026-02-18 Sung-Jan Lin Methods for treating corneal injuries

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
JP2013527222A (ja) 2010-06-03 2013-06-27 ラオフ・レキク 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン
JP2013544275A (ja) 2010-12-03 2013-12-12 ラオフ・レキク 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985897A (en) * 1973-12-21 1976-10-12 Mead Johnson & Company Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines
SE8701258D0 (sv) * 1987-03-26 1987-03-26 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
EP2311793A1 (en) 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
WO2011068786A2 (en) * 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
WO2014191414A1 (en) * 2013-05-28 2014-12-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Syrup formulation of salbutamol

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
JP2013527222A (ja) 2010-06-03 2013-06-27 ラオフ・レキク 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン
JP2013544275A (ja) 2010-12-03 2013-12-12 ラオフ・レキク 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物

Also Published As

Publication number Publication date
MA45457A (fr) 2019-05-01
CN110114066A (zh) 2019-08-09
EP3474836C0 (en) 2024-01-17
CA3028924A1 (en) 2018-01-11
US20190160027A1 (en) 2019-05-30
WO2018007864A1 (en) 2018-01-11
TN2016000259A1 (en) 2017-10-06
JP2019524679A (ja) 2019-09-05
CN110114066B (zh) 2023-06-27
RU2018146575A3 (enExample) 2020-09-24
US11484513B2 (en) 2022-11-01
EP3474836A1 (en) 2019-05-01
EP3474836B1 (en) 2024-01-17
RU2018146575A (ru) 2020-07-28

Similar Documents

Publication Publication Date Title
CN110114066B (zh) 含沙丁胺醇的眼科药物
Lee et al. Glaucoma and its treatment: a review
EP3441069B1 (en) Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Benozzi et al. Presbyopia treatment with eye drops: an eight year retrospective study
JP2022008403A (ja) 眼の状態の治療のためのピロカルピン塩酸塩の使用
Kalouda et al. Achievements and limits of current medical therapy of glaucoma
JP5897592B2 (ja) 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物
Tătaru et al. Antiglaucoma pharmacotherapy
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
Verma et al. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema
US20220257593A1 (en) Carabachol-bromonidine formulation to enhance anti-presbyopia effects
Hsu et al. Ocular toxicities of fibroblast growth factor receptor inhibitors: a review
Barton et al. Medical management of glaucoma
Schellack et al. Glaucoma: a brief review
Gonzalez-Salinas et al. Patient considerations in cataract surgery–the role of combined therapy using phenylephrine and ketorolac
Curran Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension
Akpek et al. Current treatment strategies for age-related ocular conditions
Marais et al. The medical management of glaucoma
RU2774971C2 (ru) Офтальмологическое лекарственное средство, содержащее сальбутамол
CA3028924C (en) Salbutamol-containing ophthalmic medicament
Vetrugno et al. Primary open angle glaucoma: an overview on medical therapy
Costagliola et al. Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension
Stradiotto et al. Glaucoma pharmacology
Abu Bakar et al. Medical Management of Open-Angle Glaucoma: Focus on Mechanisms of Action and Adverse Drug Reactions
RU2607291C1 (ru) Способ лечения первичной глаукомы у больных с сопутствующей артериальной гипертензией

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221110

R150 Certificate of patent or registration of utility model

Ref document number: 7176960

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees